Homepage Top Section2

The US technology company signed a letter of interest (LOI) with the DFC to secure a loan to establish Kodak Pharmaceuticals, a new business unit that will engage

Currently, DS-1062 is being developed for the treatment of non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). The TROP2 directed DXd antibody drug conjugate (ADC) is

NIAID is part of the National Institutes of Health, which is an agency of the US Department of Health and Human Services. The trial will target patients who

Gilead is also provided with an exclusive option to purchase the remaining stake in Tizona for up to an additional $1.2bn. The deal is also comprised of an

The companies have signed a collaboration agreement for the research, development, manufacturing and commercialisation of up to five messenger RNA (mRNA)-based vaccines and monoclonal antibodies (mAbs) to eliminate

The in-human study follows positive pre-clinical results for the treatment candidate, as well as successive approval of the investigational new drug application by the Korean Ministry of Food

Tremfya is a fully human monoclonal antibody that binds selectively to the p19 subunit of interleukin (IL)-23 and prevents its interaction with the IL-23 receptor, as per Janssen.

The deal gives Roche exclusive rights for the co-development and commercialisation of pralsetinib outside the US with the exclusion of Mainland China, Hong Kong, Macau, and Taiwan. In

The EC approval allows using Lynparza as a maintenance treatment for adult patients with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed